The pandemic affected laser scanning technology stock MicroVision significantly in 2020. This can be seen from the four quarters’ performance:
- In Q1 2020, MicroVision earned revenue worth $1.5 million, lesser than the $1.9 million it had earned in Q1 2019. Net loss of $4.9 million for Q1 2020 was lesser than the net loss incurred during Q1 2019, $8.1 million.
- Q2 2020 revenue for MicroVision was reported at $0.6 million. This was a decline from the $1.2 million the company had earned in Q2 2019. Net loss was reported at $2.3 million, lesser than the massive $9 million incurred in Q2 2019.
- Q3 2020 revenue for the company also totaled $0.6 million while it had earned $1.2 million in Q3 2019. Net loss was reported at $2.8 million, significantly lesser than the $6.1 million net loss incurred during Q3 2019.
- For Q4 2020, the company reported revenue worth $0.4 million, a year-over-year decline of 91.42%. Net loss was reported at $3.5 million.
Gilead Sciences ($GILD)
Biopharm company Gilead Sciences had a great opportunity with its Covid-19 treatment Veklury. But the company faced some setbacks with WHO recommending against using it. As a result, it struggled in 2020:
- During Q1 2020, Gilead earned total revenue worth $5.5 billion. This was a 5% growth over the revenue from Q1 2019. Net income for Q1 2020 was reported at $1.6 billion which was a 21% drop from the corresponding quarter in 2019.
- Q2 2020 revenue was reported to be $5.1 billion compared to the $5.7 billion from Q2 2019.
- During Q3 2020, Gilead experienced total revenue worth $6.6 billion which was a 17% growth over the $5.6 billion earned in Q3 2019.
- For Q4 2020, the biopharm giant attained product sales worth $7.3 billion, a 26% growth year-over-year.
The pandemic and the resultant shutdown increased the reliance of people on online working and other online activities. There was also a heightened demand for consumer electronics. That has helped chip making companies such as Intel:
- In Q1 2020, Intel attained revenue worth $19.8 billion. That was a 23% year-over-year gain indicating minimal impact of Covid-19.
- For Q2 2020, Intel reported GAAP revenue worth $19.7 billion. That was a 20% year-over-year growth.
- Q3 saw Intel attain revenue worth $18.3 billion. It was a year-over-year decline of 4%. Data-centric revenue also experienced a decline of 10%.
- Q4 revenue was reported at $20 billion, a year-over-year decline of 1%.
Procter & Gamble ($PG)
Though Covid-19 should usually affect retail, consumer goods are an absolute necessity. That must be why Procter & Gamble, which has a range of consumer goods brands in its arsenal, managed to raise its net sales and income in 2020:
- For Q1 2020, Procter & Gamble reported net sales worth $17.8 billion.
- During Q2 2020, the company reported revenue worth $18.24 billion which was marginally lesser than expectations of $18.37 billion. Net income was reported at $3.72 billion.
- Q3 2020 saw the company attain revenue worth $17.21 billion. Net income was reported at $2.92 billion.
- Q4 net income for P&G was reported at $2.8 billion, an improvement from the $5.2 billion loss in Q4 2019.
The content of this message and its attachments are intended only for the informational and educational use for the intended recipient and may contain confidential and privileged information. If you are not the intended recipient, any dissemination, distribution, or copying of this message or its attachments is prohibited. If you received this message in error, please notify the sender by replying to this email immediately and delete this message and its attachments from your computer. This content does not constitute an offer to sell or a solicitation to buy any security or instrument which may be referenced upon the site, or an offer to provide advisory or other services by the writer or company employing the writer in any jurisdiction in which such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. All communications sent to or from TradeZero, Inc. are subject to archive and review by TradeZero, Inc. and by regulatory and law enforcement authorities. We explicitly disclaim all liability for any action taken based on any information contained in this writing.